Physician profile
Wendell Smith
NPI 1578556619
$3,582.54
in general payments reported to CMS, 2019-2025
33 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $139 · 2021: $12.27 · 2022: $400 · 2023: $731 · 2024: $828 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.64 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $396.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $385.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $362.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $320.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.90 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $179.60 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $161.93 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $127.38 | 2019-2025 | |
| Edwards Lifesciences Corporation | $113.69 | 2019 | |
| Merck Sharp & Dohme LLC | $94.35 | 2020-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Exact Sciences Corporation | $91.57 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $70.49 | 2019-2025 | |
| Corcept Therapeutics | $60.01 | 2024-2025 | Korlym |
| Abbott Laboratories | $58.65 | 2024-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57.04 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $54.81 | 2024-2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $48.47 | 2024-2025 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $46.35 | 2019-2023 | Seglentis, Livalo |
| Dexcom, INC. | $37.78 | 2022-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $34.96 | 2022-2024 | Yupelri |
| Exeltis, USA INC. | $30.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.37 | 2024-2025 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $29.34 | 2023-2025 | Contrave |
| Amgen INC. | $28.83 | 2024-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $28.62 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $24.02 | 2025 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.59 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.53 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.04 | 2022 | |
| Atland Pharmaceuticals, LLC | $13.88 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Boston Scientific Corporation | $13.79 | 2019 | |
| Avion Pharmaceuticals | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.